

WOMEN AND LUNG CANCER RESEARCH AND
PREVENTIVE SERVICES ACT OF 2025

NOVEMBER 18, 2025.—Committed to the Committee of the Whole House on the
State of the Union and ordered to be printed

Mr. GUTHRIE, from the Committee on Energy and Commerce,
submitted the following

R E P O R T

[To accompany H.R. 2319]

The Committee on Energy and Commerce, to whom was referred the bill (H.R. 2319) to direct the Secretary of Health and Human Services to conduct a review to evaluate the status of research on lung cancer in women and underserved populations, and for other purposes, having considered the same, reports favorably thereon without amendment and recommends that the bill do pass.

CONTENTS

	Page
Purpose and Summary	2
Background and Need for Legislation	2
Committee Action	2
Committee Votes	3
Oversight Findings and Recommendations	6
New Budget Authority, Entitlement Authority, and Tax Expenditures	6
Congressional Budget Office Estimate	6
Federal Mandates Statement	6
Statement of General Performance Goals and Objectives	6
Duplication of Federal Programs	6
Related Committee and Subcommittee Hearings	6
Committee Cost Estimate	7
Earmark, Limited Tax Benefits, and Limited Tariff Benefits	7
Advisory Committee Statement	7
Applicability to Legislative Branch	7
Section-by-Section Analysis of the Legislation	7
Changes in Existing Law Made by the Bill, as Reported	8

PURPOSE AND SUMMARY

H.R. 2319, Women and Lung Cancer Research and Preventive Services Act of 2025, requires the Department of Health and Human Services (HHS) to conduct an interagency review on the status of, and identify research related to, women and underserved populations with lung cancer. The review would include assessments of current research and access to prevention services, the availability of research opportunities regarding prevention, detection, and treatment, and recommendations for national public education and screening strategies.

BACKGROUND AND NEED FOR LEGISLATION

Lung cancer is the third most common cancer in the United States.¹ Worldwide, over 600,000 women die of lung cancer each year.² About 10 to 20 percent of lung cancers, or 20,000 to 40,000 lung cancers each year, happen in people who never smoked or smoked fewer than 100 cigarettes in their lifetime.³ A better understanding of additional risk factors beyond smoking cigarettes is needed for more effective screening, diagnosis, treatment, and public health strategies, particularly around women and underserved populations.

H.R. 2319 would help advance both existing research and emerging opportunities needed to reduce lung cancer mortality—especially among women, who face unique risks and outcomes. The bipartisan legislation will provide a complete review of the research by requiring an interagency review by HHS, working with the Departments of Defense and Veterans Affairs, to evaluate the status and identify opportunities for research on women and lung cancer, including access to preventative services, strategic public awareness and education campaigns on lung cancer.

COMMITTEE ACTION

On February 14, 2024, the Subcommittee on Health held a hearing on H.R. 4534.⁴ The title of the hearing was “Legislative Proposals to Support Patients and Caregivers.” The Subcommittee received testimony from:

- Andy Shih, PhD, Chief Science Officer, Autism Speaks;
- Corey Feist, JD, MBA, Co-Founder and CEO, Dr. Lorna Breen Heroes’ Foundation;
- Joanne Pike, DrPH, President and CEO, Alzheimer’s Association;
- Gordon Tomaselli, MD, Former President, American Heart Association; Marilyn and Stanley M. Katz Dean, Emeritus and Professor of Medicine, Albert Einstein College of Medicine; Adjunct Professor of Medicine, Johns Hopkins University School of Medicine;

¹*Lung Cancer Statistics*, U.S. CENTERS FOR DISEASE CONTROL AND PREVENTION (Jun. 13, 2024), https://www.cdc.gov/lung-cancer/statistics/?CDC_AAref_Val=https://www.cdc.gov/cancer/lung/statistics/index.htm.

²*Women and Lung Cancer*, LUNG CANCER RESEARCH FOUNDATION, <https://www.lungcancerresearchfoundation.org/for-patients/women-and-lc/>.

³*Lung Cancer Among People Who Never Smoked*, U.S. CENTERS FOR DISEASE CONTROL AND PREVENTION (Dec. 4, 2023), <https://www.cdc.gov/lung-cancer/nonsmokers/index.html#:~:text=cancer%2C%20and%20asbestos.,In%20the%20United%20States%2C%20about%2010%25%20to%2020%25%20of%2C900%20of%20these%20lung%20cancers.>

⁴Provisions of H.R. 4534 were reintroduced in the 119th Congress as H.R. 2319.

- Michelle Whitten, President, CEO, and Co-Founder, Global Down Syndrome Foundation;
- Randy Strozyk, President, American Ambulance Association; and
- Christina Annunziata, MD, PhD, Senior Vice President of Extramural Discovery Science, American Cancer Society.

On May 16, 2024, the Subcommittee on Health met in open markup session and forwarded H.R. 4534, as amended, to the full Committee by a record vote of 21 yeas to 0 nays.

On June 12, 2024, the full Committee on Energy and Commerce met in open markup session and ordered H.R. 4534, as amended, favorably reported to the House by a record vote of 44 yeas and 0 nays.

On April 29, 2025, the full Committee on Energy and Commerce met in open markup session and ordered H.R. 2319 favorably reported to the House by a voice vote.

COMMITTEE VOTES

Clause 3(b) of rule XIII requires the Committee to list the record votes on the motion to report legislation and amendments thereto. The following reflects the record votes taken during the Committee consideration:

**COMMITTEE ON ENERGY AND COMMERCE
119TH CONGRESS
ROLL CALL VOTE # 17**

BILL: H.R. 2319

AMENDMENT: HR2319_01, offered by Rep. Matsui

DISPOSITION: Not agreed to, by a roll call vote of 21 yeas and 25 nays.

REPRESENTATIVE	YEAS	NAYS	PRESENT	REPRESENTATIVE	YEAS	NAYS	PRESENT
Mr. Guthrie		X		Mr. Pallone	X		
Mr. Latta		X		Ms. DeGette	X		
Mr. Griffith		X		Ms. Schakowsky	X		
Mr. Bilirakis		X		Ms. Matsui	X		
Mr. Hudson		X		Ms. Castor	X		
Mr. Carter (GA)		X		Mr. Tonko	X		
Mr. Palmer		X		Ms. Clarke			
Mr. Dunn		X		Mr. Ruiz	X		
Mr. Crenshaw		X		Mr. Peters	X		
Mr. Joyce		X		Mrs. Dingell	X		
Mr. Weber		X		Mr. Veasey	X		
Mr. Allen		X		Ms. Kelly			
Mr. Balderson		X		Ms. Barragán	X		
Mr. Fulcher		X		Mr. Soto	X		
Mr. Pfluger				Ms. Schrier	X		
Mrs. Harshbarger		X		Ms. Trahan	X		
Mrs. Miller-Meeks				Ms. Fletcher	X		
Mrs. Cammack		X		Ms. Ocasio-Cortez	X		
Mr. Obernolte				Mr. Auchincloss	X		
Mr. James				Mr. Carter (LA)			
Mr. Bentz		X		Mr. Menendez	X		
Mrs. Houchin		X		Mr. Mullin	X		
Mr. Fry		X		Mr. Landsman	X		
Ms. Lee		X		Ms. McClellan	X		
Mr. Langworthy		X					
Mr. Kean		X					
Mr. Rulli		X					
Mr. Evans							
Mr. Goldman		X					
Mrs. Fedorchak		X					

04/29/2025

**COMMITTEE ON ENERGY AND COMMERCE
119TH CONGRESS
ROLL CALL VOTE # 18**

BILL: H.R. 2319

AMENDMENT: H2319-AMD_01, offered by Rep. Barragan

DISPOSITION: Not agreed to, by a roll call vote of 21 yeas and 25 nays.

REPRESENTATIVE	YEAS	NAYS	PRESENT	REPRESENTATIVE	YEAS	NAYS	PRESENT
Mr. Guthrie		X		Mr. Pallone	X		
Mr. Latta		X		Ms. DeGette	X		
Mr. Griffith		X		Ms. Schakowsky	X		
Mr. Bilirakis		X		Ms. Matsui	X		
Mr. Hudson		X		Ms. Castor	X		
Mr. Carter (GA)		X		Mr. Tonko	X		
Mr. Palmer		X		Ms. Clarke			
Mr. Dunn		X		Mr. Ruiz	X		
Mr. Crenshaw		X		Mr. Peters	X		
Mr. Joyce		X		Mrs. Dingell	X		
Mr. Weber		X		Mr. Veasey			
Mr. Allen		X		Ms. Kelly			
Mr. Balderson		X		Ms. Barragán	X		
Mr. Fulcher		X		Mr. Soto	X		
Mr. Pfluger				Ms. Schrier	X		
Mrs. Harshbarger		X		Ms. Trahan	X		
Mrs. Miller-Meeks				Ms. Fletcher	X		
Mrs. Cammack		X		Ms. Ocasio-Cortez	X		
Mr. Obernolte		X		Mr. Auchincloss	X		
Mr. James				Mr. Carter (LA)	X		
Mr. Bentz		X		Mr. Menendez	X		
Mrs. Houchin		X		Mr. Mullin	X		
Mr. Fry		X		Mr. Landsman	X		
Ms. Lee		X		Ms. McClellan	X		
Mr. Langworthy		X					
Mr. Kean		X					
Mr. Rulli							
Mr. Evans							
Mr. Goldman		X					
Mrs. Fedorchak		X					

04/29/2025

OVERSIGHT FINDINGS AND RECOMMENDATIONS

Pursuant to clause 2(b)(1) of rule X and clause 3(c)(1) of rule XIII, the Committee held a hearing and made findings that are reflected in this report.

NEW BUDGET AUTHORITY, ENTITLEMENT AUTHORITY,
AND TAX EXPENDITURES

Pursuant to clause 3(c)(2) of rule XIII, the Committee finds that H.R. 2319 would result in no new or increased budget authority, entitlement authority, or tax expenditures or revenues.

CONGRESSIONAL BUDGET OFFICE ESTIMATE

Pursuant to clause 3(c)(3) of rule XIII, at the time this report was filed, the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974 was not available.

FEDERAL MANDATES STATEMENT

The Committee adopts as its own the estimate of Federal mandates prepared by the Director of the Congressional Budget Office pursuant to section 423 of the Unfunded Mandates Reform Act.

STATEMENT OF GENERAL PERFORMANCE GOALS AND OBJECTIVES

Pursuant to clause 3(c)(4) of rule XIII, the general performance goal or objective of this legislation is to review, evaluate the status of, and identify research and educational opportunities related to lung cancer in women and certain underserved populations.

DUPLICATION OF FEDERAL PROGRAMS

Pursuant to clause 3(c)(5) of rule XIII, no provision of H.R. 2319 is known to be duplicative of another Federal program, including any program that was included in a report to Congress pursuant to section 21 of Public Law 111–139 or the most recent Catalog of Federal Domestic Assistance.

RELATED COMMITTEE AND SUBCOMMITTEE HEARINGS

Pursuant to clause 3(c)(6) of rule XIII, the following related hearing was used to develop or consider H.R. 2319:

- On February 14, 2024, the Subcommittee on Health held a hearing on H.R. 4534.⁵ The title of the hearing was “Legislative Proposals to Support Patients and Caregivers.” The Subcommittee received testimony from:
 - Andy Shih, PhD, Chief Science Officer, Autism Speaks;
 - Corey Feist, JD, MBA, Co-Founder and CEO, Dr. Lorna Breen Heroes’ Foundation;
 - Joanne Pike, DrPH, President and CEO, Alzheimer’s Association;
 - Gordon Tomaselli, MD, Former President, American Heart Association; Marilyn and Stanley M. Katz Dean, Emeritus and Professor of Medicine, Albert Einstein Col-

⁵ Provisions of H.R. 4534 were reintroduced in the 119th Congress as H.R. 2319.

lege of Medicine; Adjunct Professor of Medicine, Johns Hopkins University School of Medicine;

- Michelle Whitten, President, CEO, and Co-Founder, Global Down Syndrome Foundation;
- Randy Strozyk, President, American Ambulance Association; and
- Christina Annunziata, MD, PhD, Senior Vice President of Extramural Discovery Science, American Cancer Society.

COMMITTEE COST ESTIMATE

Pursuant to clause 3(d)(1) of rule XIII, the Committee adopts as its own the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974. At the time this report was filed, the estimate was not available.

EARMARK, LIMITED TAX BENEFITS, AND LIMITED TARIFF BENEFITS

Pursuant to clause 9(e), 9(f), and 9(g) of rule XXI, the Committee finds that H.R. 2319 contains no earmarks, limited tax benefits, or limited tariff benefits.

ADVISORY COMMITTEE STATEMENT

No advisory committees within the meaning of section 5(b) of the Federal Advisory Committee Act were created by this legislation.

APPLICABILITY TO LEGISLATIVE BRANCH

The Committee finds that the legislation does not relate to the terms and conditions of employment or access to public services or accommodations within the meaning of section 102(b)(3) of the Congressional Accountability Act.

SECTION-BY-SECTION ANALYSIS OF THE LEGISLATION

Section 1. Short title

Section 1 provides that the Act may be cited as the “Women and Lung Cancer Research and Preventative Services Act of 2025”.

Section 2. Interagency review to evaluate and identify opportunities for the acceleration of research on lung cancer in women and underserved populations, greater access to preventative services, and strategic public awareness and education campaigns

Section 2 requires the Secretary of Health and Human Services (HHS), in consultation with the Secretary of Defense and Secretary of Veteran Affairs, to conduct an interagency review on the status of, and identify research and education opportunities related to, women and underserved populations with lung cancer. The review shall include assessments of current research and access to prevention services, the availability of research opportunities regarding prevention, detection, and treatment, and recommendations for national public education and screening strategies. This section also requires the Secretary of HHS to submit a report to Congress detailing the results of the review within two years of enactment.

CHANGES IN EXISTING LAW MADE BY THE BILL, AS REPORTED
This legislation does not amend any existing Federal statute.

